Chauvin, Maëva
Garambois, Véronique
Colombo, Pierre-Emmanuel
Chentouf, Myriam
Gros, Laurent
Brouillet, Jean-Paul
Robert, Bruno
Jarlier, Marta
Dumas, Karen
Martineau, Pierre
Navarro-Teulon, Isabelle
Pépin, David
Chardès, Thierry
Pèlegrin, André
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-LABX-53)
Ligue Nationale contre le Cancer, France
SIRIC Montpellier-Cancer (INCa-DGOS-Inserm 6045)
Inserm-Transfert, France
Article History
Received: 31 August 2020
Accepted: 12 January 2021
First Online: 26 January 2021
Competing interests
: Maëva Chauvin, Myriam Chentouf, Pierre Martineau, Bruno Robert, and André Pèlegrin are inventors of a patent “ANTI-MÜLLERIAN INHIBITING SUBSTANCE ANTIBODIES AND USES THEREOF” filed on 2019, September, 27. Maëva Chauvin, Thierry Chardès, Isabelle Navarro-Teulon and André Pèlegrin are inventors of a patent “USE OF MÜLLERIAN INHIBITING SUBSTANCE INHIBITORS FOR TREATING CANCER” filed on 2019, September, 27. David Pépin is inventor of the patent “MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES”, WO2014164981A1. The other authors declare no competing interests.